GlobeNewsWire
22 Feb 2026, 21:00 UTC · 30w ago
Verdict
Headline takes no side. We score DYN +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Dyne Therapeutics will present new long-term data showing potential preservation of cardiopulmonary function from the DELIVER trial of z-rostudirsen in DMD.
So whatPositive long-term cardiopulmonary data for a DMD treatment is a high-value clinical milestone that can significantly increase the probability of regulatory success and market valuation.
More positive than 93% of claims this week
The company will present the design for a global Phase 3 trial of z-basivarsen for the treatment of myotonic dystrophy type 1 (DM1).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Dyne will present preclinical data for DYNE-401, showing potential for addressing Pompe disease with low and infrequent dosing.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company announced positive clinical results for its DMD trial and the design of a Phase 3 trial for DM1, showcasing a strong pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
12h ago
+9.1%
Price agrees with the score
$16.23 vs $14.88 close before publication (Feb 20) · not market-adjusted
DYN chart →
